New combo aims to shrink tough breast tumors before chemo

NCT ID NCT06353997

First seen Nov 19, 2025 · Last updated May 05, 2026 · Updated 18 times

Summary

This study tests whether adding an experimental drug (INBRX-106) to an approved immunotherapy (pembrolizumab) can shrink tumors in people with stage II or III triple-negative breast cancer before they start standard chemotherapy. About 12 adults with measurable tumors will receive two cycles of the combo, then continue with usual care. The goal is to see if this approach improves response and makes surgery more effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ellison Institute of Technology (EITM)

    RECRUITING

    Los Angeles, California, 90064, United States

    Contact Phone: •••-•••-••••

  • Providence Portland Cancer Institute - Franz Clinic

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

  • Providence St. Vincent Medical Center

    RECRUITING

    Portland, Oregon, 97225, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Swedish Cancer Institute

    NOT_YET_RECRUITING

    Seattle, Washington, 98104, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.